Plaintiffs, retailers and Iovate Health Sciences Inc. have reached a $14 million settlement agreement resolving false advertising class actions stemming from sales of the weight-loss supplement Hydroxycut before the U.S. Food and Drug Administration pulled the product from shelves in 2009. In re Hydroxycut Mktg. & Sales Practices Litig. No. 09-02087 (U.S. Dist. Ct., S.D. Cal., motion filed April 21, 2014). The settlement follows a similarly structured $25.3 million proposed deal rejected by Judge Barry Ted Moskowitz in November 2013 and a January 2014 ruling declaring that if the claims against the retailers were to succeed, the plaintiffs would have to prove that the retailers directly participated in or controlled ads for Hydroxycut. The $14 million settlement includes $7 million in Iovate products that do not include the allegedly dangerous or ineffective ingredients in Hydroxycut as well as $7 million in cash, with cy pres distribution of any remaining money to public health policy nonprofit Changelab Solutions.